Tropicamide
Tropicamide is a short-acting antimuscarinic agent that blocks muscarinic receptors in the iris sphincter and ciliary muscle, producing mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). It is widely used in ophthalmic practice for fundus examination, evaluation of glaucoma, and refraction testing, with effects lasting 4-6 hours. Its rapid onset and shorter duration compared to atropine make it preferred for diagnostic purposes.
Peso Molecular
284,3500 g/mol
LogP
1,50
TPSA
53,40 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1
InChI
InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3
Molecular Formula
C17H20N2O2
HBD / HBA
1 / 3
Ligações Rotacionáveis
6
Átomos Pesados
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Tropicamide is a short-acting antimuscarinic agent that blocks muscarinic receptors in the iris sphincter and ciliary muscle, producing mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). It is widely used in ophthalmic practice for fundus examination, evaluation of glaucoma, and refraction testing, with effects lasting 4-6 hours. Its rapid onset and shorter duration compared to atropine make it preferred for diagnostic purposes.
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Yes, Tropicamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200604. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5593. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tropicamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tropicamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tropicamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tropicamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tropicamide"></drugfyi-drug>